Table 2 Survival for GMS according to low- and high-risk disease and location of cancer in the validation cohort (n = 862).
GroupGMS category | Disease-free survival | Relapse-free survival | |||||||
|---|---|---|---|---|---|---|---|---|---|
N | 5-year DFS (%; SE) | Events (n = 541) | HR (95% CI) | P | 5-year RFS (%; SE) | Events (n = 271) | HR (95% CI) | P | |
Full cohort | Trend | 0.003 | Trend | <0.001 | |||||
0 | 300 | 71 (3) | 168 | 1.0 (reference) | 83 (2) | 61 | 1.0 (reference) | ||
1 | 424 | 58 (2) | 281 | 1.30 (1.08–1.58) | 0.007 | 70 (2) | 141 | 1.82 (1.35-2.46) | <0.001 |
2 | 138 | 46 (4) | 92 | 1.50 (1.16–1.93) | 0.002 | 51 (4) | 69 | 3.09 (2.19-4.36) | <0.001 |
TNM I–II (low risk) | Trend | 0.89 | Trend | <0.001 | |||||
0 | 201 | 73 (3) | 113 | 1.0 (reference) | 88 (2) | 29 | 1.0 (reference) | ||
1 | 244 | 70 (3) | 148 | 1.06 (0.83–1.35) | 0.65 | 84 (2) | 49 | 1.42 (0.90–2.25) | 0.13 |
2 | 54 | 57 (7) | 29 | 1.06 (0.70–1.59) | 0.79 | 63 (7) | 21 | 3.24 (1.85–5.68) | <0.001 |
TNM II–III (high risk) | Trend | 0.003 | Trend | 0.001 | |||||
0 | 99 | 66 (5) | 55 | 1.0 (reference) | 72 (5) | 32 | 1.0 (reference) | ||
1 | 180 | 43 (4) | 133 | 1.67 (1.22–2.29) | 0.001 | 51 (4) | 92 | 1.95 (1.30–2.92) | 0.001 |
2 | 84 | 38 (5) | 63 | 1.72 (1.19–2.47) | 0.003 | 43 (6) | 48 | 2.18 (1.39–3.41) | 0.001 |
Colon cancer | Trend | 0.004 | Trend | <0.001 | |||||
0 | 206 | 72 (3) | 113 | 1.0 (reference) | 84 (3) | 41 | 1.0 (reference) | ||
1 | 345 | 58 (3) | 233 | 1.38 (1.10–1.73) | 0.005 | 69 (3) | 115 | 1.88 (1.32–2.68) | 0.001 |
2 | 99 | 45 (5) | 67 | 1.57 (1.16–2.12) | 0.004 | 51 (5) | 49 | 3.15 (2.08–4.77) | <0.001 |
Rectal cancer | Trend | 0.46 | Trend | 0.003 | |||||
0 | 94 | 68 (5) | 55 | 1.0 (reference) | 80 (4) | 20 | 1.0 (reference) | ||
1 | 79 | 62 (5) | 48 | 1.07 (0.73–1.58) | 0.72 | 72 (5) | 26 | 1.66 (0.92–2.97) | 0.09 |
2 | 39 | 46 (8) | 25 | 1.35 (0.84–2.17) | 0.21 | 51 (8) | 20 | 2.95 (1.58–5.48) | 0.001 |
